Share on StockTwits

Shares of Questcor Pharmaceuticals (NASDAQ:QCOR) hit a new 52-week high during mid-day trading on Thursday , StockRatingsNetwork reports. The company traded as high as $94.87 and last traded at $94.87, with a volume of 901,726 shares trading hands. The stock had previously closed at $92.45.

A number of analysts have recently weighed in on QCOR shares. Analysts at Zacks downgraded shares of Questcor Pharmaceuticals from an “outperform” rating to a “neutral” rating in a research note on Tuesday. They now have a $97.00 price target on the stock. Separately, analysts at Mizuho downgraded shares of Questcor Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Monday, May 19th. They now have a $92.00 price target on the stock. Finally, analysts at Piper Jaffray downgraded shares of Questcor Pharmaceuticals from an “overweight” rating to a “neutral” rating in a research note on Monday, May 12th. They now have a $98.00 price target on the stock, up previously from $96.00. Seven investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $86.20.

The stock’s 50-day moving average is $90.47 and its 200-day moving average is $73.49. The company has a market cap of $5.618 billion and a P/E ratio of 17.46. Questcor Pharmaceuticals also was the recipient of a large increase in short interest in the month of June. As of June 13th, there was short interest totalling 19,245,387 shares, an increase of 8.1% from the May 30th total of 17,804,215 shares. Based on an average daily volume of 1,699,347 shares, the days-to-cover ratio is currently 11.3 days. Currently, 32.4% of the shares of the company are short sold.

Questcor Pharmaceuticals (NASDAQ:QCOR) last posted its quarterly earnings results on Monday, April 28th. The company reported $1.40 EPS for the quarter, missing the Thomson Reuters consensus estimate of $1.61 by $0.21. The company had revenue of $227.10 million for the quarter, compared to the consensus estimate of $239.81 million. During the same quarter in the prior year, the company posted $0.76 earnings per share. The company’s quarterly revenue was up 68.1% on a year-over-year basis. Analysts expect that Questcor Pharmaceuticals will post $6.89 EPS for the current fiscal year.

In other Questcor Pharmaceuticals news, Insider David Young unloaded 6,000 shares of the stock in a transaction dated Tuesday, June 24th. The stock was sold at an average price of $91.96, for a total transaction of $551,760.00. The sale was disclosed in a filing with the SEC, which is available at this link.

Questcor Pharmaceuticals, Inc (NASDAQ:QCOR) is a biopharmaceutical company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.